Background
==========

Functionally univentricular hearts (UVH) include congenital defects with hypoplasia of either the right or the left ventricle, which, as a consequence, cannot drive a pulmonary or systemic circulation alone. The natural history of UVH is poor with reported one-year survival rates less than 50% \[[@B1]\]. Introduction of palliative surgical treatment by Fontan in 1971 \[[@B2]\] has dramatically improved survival. The technique has evolved \[[@B3],[@B4]\] and is currently performed as Total Cavo-Pulmonary Connection (TCPC). Although the procedure remains palliative rather than curative, the 10-year survival rate post-surgery increased from 50% in the first Fontan patients to 90% currently \[[@B5]-[@B7]\].

The complete TCPC is typically carried out in three stages. Generally, the first stage is undertaken in the neonatal period and aims at regulating the pulmonary blood flow to an adequate level, either by reducing or increasing pulmonary flow using a pulmonary banding or a shunt, respectively, but also securing that systemic perfusion and mixing remains unobstructed. The second stage is the bidirectional Glenn procedure, where the superior vena cava is anastomosed to the pulmonary artery. In the third stage, the TCPC circulation is established by diverting the inferior vena cava to the pulmonary artery, thus allowing almost complete systemic venous bypass of the heart. The second and third stages are usually performed between six months and three years of age.

The prevalence of TCPC patients has steadily increased over the past decades. A recent Danish population-based study found 43 surviving UVH patients per million inhabitants, 37 of whom were palliated with Fontan/TCPC \[[@B8]\]. Despite improved survival, TCPC is still associated with high morbidity. Myocardial dysfunction, arrhythmias, thromboembolic events, neuropsychological deficits, protein-losing enteropathy, and reduced exercise capacity are among the most commonly reported long-term complications \[[@B9]-[@B12]\].

In the TCPC, pulmonary flow is driven without support from a sub-pulmonary ventricle. Thus, even a slight increase in pulmonary vascular resistance (PVR) may compromise the pulmonary circulation which in turn may result in decreased preload of the ventricle, limiting cardiac output (CO) and exercise tolerance \[[@B13],[@B14]\]. An increased pulmonary blood flow prior the Glenn anastomosis may contribute the elevated PVR in some patients. Furthermore, the non-pulsatile pulmonary blood-flow following the TCPC procedure may also increase PVR through remodeling, as shown in an animal model \[[@B15]\]. This is supported by the fact that raised levels of the potent vasoconstrictor endothelin-1 correlate with increased PVR and failure of the Fontan circulation \[[@B11],[@B16]\]. Furthermore, endothelin-1 is elevated in many UVH patients before surgical palliation \[[@B17]\]. This raises the question whether pulmonary vasodilators may have a role in the treatment of this patient group.

Endothelin receptor antagonists (ERA) not only have an immediate vasodilating effect on the pulmonary vasculature, but also a long term effect in its inhibition of the structural remodeling of the pulmonary microcirculation, thus theoretically improving exercise capacity in patients with TCPC circulation. Accordingly, small studies have shown that oral treatment with pulmonary vasodilators, including ERAs improves hemodynamics and exercise capacity after TCPC operation \[[@B18]-[@B21]\].

The TEMPO trial is a randomized, placebo-controlled and double-blinded study. The aim is to investigate whether Bosentan, an ERA, can improve exercise capacity and is safe to administer to TCPC patients.

Methods/Design
==============

Participants
------------

The participants are recruited among all registered TCPC patients over 12 years of age from the four participating tertiary centers; two Danish centers; Copenhagen University Hospital, Rigshospitalet and Aarhus University Hospital, Skejby and two Swedish centers; Karolinska Institutet in Stockholm and Lund University Hospital. Subjects who fulfill the inclusion criteria and do not meet any exclusion criteria (Table  [1](#T1){ref-type="table"}) are contacted, aiming for 78 participants. All participants receive written and oral information in their own language, and sign an informed consent form before enrollment.

###### 

**In**-/**exclusion criteria**

  ------------------------ ----------------------------------------------------------------------------------------------------------------------------------------
  **Inclusion criteria**   
  •                        Fontan/TCPC operated
  •                        Expected clinical stability \> 3 months, evaluated by investigator from clinical record
  **Exclusion criteria**   
  •                        Age \< 12 years
  •                        Severe heart failure (NYHA-class IV)
  •                        Oxygen saturation \< 85% at rest
  •                        Pre-existing liver condition (transaminases 2x \> upper reference limit)
  •                        Renal failure (creatinin \> 150 mmol/l)
  •                        Restrictive Fontan circuit
  •                        History of work induced severe arrhythmia
  •                        Systolic blood pressure below 80% of reference (\< 88 mmHg)
  •                        Use of any of following drugs: Fluconazole, Ketoconazole, CyclosporineA, Lopinavir, Ritonavir, Rifampicin, Carbamazepine and Phenytoin
  •                        Severe extra-cardiac condition e.g. neurological impairment
  •                        For women: Positive HCG or no use of contraception\*
  •                        History of low compliance
  ------------------------ ----------------------------------------------------------------------------------------------------------------------------------------

TCPC: Total Cavo-Pulmonary Connection, NYHA: New York Heart Association, HCG: Human Chorionic Gonadotropin, \*: contraception includes celibacy.

Demographic and diagnostic data as well as blood samples are recorded at baseline (Table  [2](#T2){ref-type="table"}).

###### 

Baseline data

  -------------------------------- ----------------------
  **Demographic and diagnostic**   
  Gender                           Male/female
  Age                              Years
  Ventricular anatomy              Right/left/mixed
  Basic diagnosis                   
  Patent fenestration              Yes/no
  Current medication                
  **Blood sample**                 **Stool sample**
  Liver enzymes                    Fecal α1-antitrypsin
  Albumin                           
  Protein                           
  Pro-Brain Natriuretic Peptide     
  C-terminal proendothelin-1        
  -------------------------------- ----------------------

Endpoints
---------

Endpoints are given in Table  [3](#T3){ref-type="table"}. Maximal oxygen consumption (peakVO~2~), pulmonary blood flow, oxygen consumption at anaerobic threshold (VO~2~ \[AT\]) and maximal work load are all calculated from results of a bicycle ergometer test, performed at Institute of Sports Medicine Copenhagen, as described below. Blood samples and SF36 quality of life questionnaire are obtained at the baseline and endpoint visits. NYHA class is determined before the bicycle test. Fecal samples for α-1 antitrypsin are collected by the participant at home and subsequently sent in a provided envelope for analysis. It is optional for participants to partake in this endpoint.

###### 

Endpoints

  ------------------------- ------------------------------------------------------
  **Primary endpoint**      
  •                         peakVO~2~ (ml/min, ml/min/kg body weight)
  **Secondary endpoints**   
  •                         VO~2~ (AT) (ml/min)
  •                         Maximal load (Watt)
  •                         Pulmonary blood flow (by Stringer-Wassermann method)
  •                         NYHA class
  •                         SF36 quality of life questionnaire
  •                         proBNP (pmol/l)
  •                         Fecal α1-antitrypsin (g/kg)
  ------------------------- ------------------------------------------------------

PeakVO2: maximal oxygen consumption in test, VO~2~ (AT): oxygen consumption at anaerobic threshold, NYHA: New York Heart Association, proBNP: pro-Brain Natriuretic Peptide.

Bicycle ergometer test
----------------------

The primary endpoint is improvement in peakVO~2~ (ml/min and ml/min/kg body weight) obtained during a bicycle ergometer test. All tests are performed on the same equipment (Monark Ergomedic 839E, Monark Exercise AB, Sweden), at the same site and with the same staff present. An individualized incremental protocol is chosen for each patient, with the purpose of reaching maximal effort within 6--12 minutes. All participants start with one to two minutes warm-up. After this, the test protocol starts at either 20 Watt increasing stepwise 20 Watt/min or starting at 25 Watt increasing 25 Watt/min. Before each test the flow-meter and gas analyzer are calibrated. During the test electrocardiography and percutaneous oxygen saturation are measured continuously. The participants wear a mask with a TripleV flow-meter (Erich Jaeger GmbH, Germany) to measure respiration volume, and a tube for breath-by-breath sampling to measure O~2~ and CO~2~ concentrations via Masterscreen CPX (CareFusion, San Diego, CA, USA). All measures are given as the average over 15 seconds intervals subtracting the highest and lowest value. Pulmonary blood flow is calculated continuously by the test software using the Stringer-Wassermann method \[[@B22]\]. Only participants without patent fenestration of the TCPC tunnel are considered for this endpoint.

The principal investigator is present at all tests to motivate patients to reach maximal effort in both pre- and post-treatment tests. Furthermore, Respiratory Exchange Ratio (RER) is measured, and a value of ≥1.1 is considered acceptable as an indicator of maximal effort. Patients who are unable to reach RER ≥1.1 in either the pre- or post-treatment test will not be considered in the statistical analysis for the primary endpoint. PeakVO~2~ is defined as the 15 second interval with the highest value of VO~2~.

Anaerobic threshold is defined as the first 15 second interval where the average RER passes the value 1.0 without falling below 1.0 later \[[@B23]\].

It is considered unnecessary to make the participants undergo a "dummy test" before enrollment since patients in the Scandinavian countries are familiar with bicycles, and exercise testing is frequently used in the clinical follow-up of TCPC patients. Furthermore, this was confirmed in a recent feasibility study where six Danish patients with congenital heart disease and one healthy adolescent were tested twice within six weeks, demonstrating excellent reproducibility, with an intra-class correlation coefficient of 0.99 \[[@B24]\].

Trial design
------------

The trial is a randomized, double-blinded, placebo-controlled clinical trial. Patients with TCPC palliated UVH, are eligible for enrollment. Participants are randomized 1:1 to parallel groups of treatment or placebo (Figure  [1](#F1){ref-type="fig"}). The Bosentan dose regimen is the same as used in patients with pulmonary arterial hypertension \[[@B25]\]. Participants receive oral placebo or Bosentan 62.5 mg b.i.d. for two weeks followed by 125 mg b.i.d. for 12 weeks. For patients with a body weight below 35 kg, the dose is halved i.e. 31.25 mg b.i.d. for two weeks and 62.5 mg b.i.d. for 12 weeks.

![**Study design.**b.i.d.: twice daily, Cont.: continue.](1471-2261-13-36-1){#F1}

Medication/Randomization
------------------------

At enrollment participants receive a package with four glasses each containing 70 tablets; one with placebo or Bosentan 62.5 mg tablets for the first two weeks, and three with placebo or Bosentan 125 mg for the remaining 12 weeks. The study medication is delivered by Actelion Pharmaceuticals packed, labeled and numbered. The packages are randomized when received by the investigators. Randomization is done via a computerized model, and only the manufacturer knows the randomization status.

At each visit the remaining tablets are counted to control compliance. Patients who take at least 80% of the intended tablets are defined as "per protocol" whereas the rest are counted as "intention to treat".

Safety/visits
-------------

During the study, participants will have a total of five visits (Table  [4](#T4){ref-type="table"}), three of which are intermediary controls to ensure safety. All tests at the baseline and final visit are performed in Copenhagen, whereas the first intermediary visit after two weeks must take place in one of the four participating tertiary centers. Control visits may take place at a local hospital or at the general practitioner's office, in case this is more convenient to the participant.

###### 

Visits

  **Visit/week**                                                           **Baseline**   **Increase medication**   **Safety visit**   **Safety visit**   **Endpoint**
  ----------------------------------------------------------------------- -------------- ------------------------- ------------------ ------------------ --------------
  Place                                                                        Cph               Tertiary                Local              Local             Cph
  Time window                                                                 Day 0              Day 10-18             Day 35-49          Day 63-77        Day 91-105
  Bosentan dose after visit                                                62.5 mg x 2          125 mg x 2                None                           
  In-/exclusion criteria, informed consent                                      X                                                                               
  Exercise test, SF36 q.o.l., α1-AT                                             X                                                                              X
  Blood pressure, heart rate, SAT                                               X                    X                     X                  X                X
  Blood pressure/hypotension control                                            X                    X                                                          
  Compliance control and adverse effects                                                             X                     X                  X                X
  CT-proET-1, IgA, IgG, Pro-BNP, albumin, protein, LDH                          X                                                                              X
  ALAT, ASAT, bilirubin, creatinine, PCV, Hb, thrombocytes, (women) HCG         X                    X                     X                  X                X

Cph: Copenhagen University Hospital, Rigshospitalet, Tertiary: Any of the four participating tertiary centers, Local: Local hospital including tertiary center or general practitioners office, SF36 q.o.l.: SF36 quality of life questionnaire, α1-AT: fecal α1-antitrypsin, SAT: transcutaneous oxygen saturation, CT-proET-1: C-terminal proendothelin-1, IgA-G: Immunoglobulin A-G, Pro-BNP: Pro-Brain Natriuretic Peptide, LDH: Lactate dehydrogenase, ALAT/ASAT: Alanine-/aspartate aminotransferase, PCV: Packed cell volume/hematocrit, Hb: Hemoglobin, HCG: Human chorionic gonadotropin.

When starting medication at baseline and when increasing the dose after two weeks a special safety measure is taken. Each participant has blood pressure, heart rate and percutaneous oxygen saturation measured before the medication is given. Blood pressure is then measured one and two hours after the medication is administered. If symptoms of hypotension and a decrease in systolic blood pressure over 20% are seen, the participant will be evaluated by clinical experts and possibly excluded.

Female participants are advised about contraception methods, and encouraged to contact the study group with any suspicion of pregnancy. At every visit s-hCG is measured.

In case of serious adverse events the medication is stopped and the patient is excluded. Moreover, adverse events (Table  [5](#T5){ref-type="table"}) lead to exclusion of the study or continuation at a lower dose of medication.

###### 

Safety measures

  **Observation**                                  **Action**
  ------------------------------------------------ ----------------------------------------------
  Systolic blood pressure \< 80 mmHg               Exclusion
  Hemoglobin \< 6.5 mmol/l                         Exclusion
  \> 10% decrease in oxygen saturation             Exclusion
  \> 10% decrease in packed cell volume            Exclusion
  \> 10% decrease in thrombocytes                  Exclusion
  Two times increase in bilirubin\*                Exclusion
  Liver transaminases 3--5 times reference limit   Continue in study at half dose of medication
  Liver transaminases \>5 times reference limit    Exclusion

\*In patients with bilirubin at baseline within the reference limits an increase to 2 x upper reference limit leads to exclusion; if bilirubin is already over reference limit at baseline, a bilirubin increase to 2 x the baseline value leads to exclusion.

Sample size calculation
-----------------------

Average peakVO~2~in adult TCPC patients is approximately 20 ml/kg/min \[[@B10]\]. Assuming that 14 weeks treatment with Bosentan compared to placebo will increase in the primary endpoint peakVO~2~by 20%, an increase of 4 ml/kg/min is expected.

The standard deviation (SD) of a single measurement of maximal VO~2~in TCPC adults is reported to range from 2.5 to 5.8 ml/kg/min \[[@B10],[@B18]\]. Thus, a weighted mean SD of 4.3 ml/kg/min is used in the calculations in this study.

The intra-patient correlation is assumed to be 0.5, and the required power is 90% at a significance level of 95%. With a paired *t*-test, the number needed in each group is 24. Exclusion due to elevated liver enzymes is expected in 5%, low medication compliance in 15%, whereas drop-outs are expected in 33% of the participants. Thus, 39 patients will be included in each group.

Discussion
==========

Surgical and medical advances in recent decades have improved the survival of children born with UVH; hence, we can expect a higher prevalence and an increasing age of patients palliated with TCPC in the future. When older, impaired exercise capacity may be an important long-term complication in TCPC patients. The TEMPO study hypothesizes that the ERA Bosentan partly may counteract this effect, particularly considering the finding of high plasma levels of endothelin-1 in UVH and TCPC palliated patients.

Current evidence is pointing toward the lack of preload reserve as the most important factor in limiting CO in TCPC patients \[[@B13],[@B14]\]. In the healthy biventricular individual, the CO is readily increased with a reduction in afterload, augmentation of ventricular contractility or increase in heart rate. The effect of these factors is dependent on an abundant preload reserve, in the absence of which CO increase would suffer. In the Fontan circulation there is limited preload reserve due to the passive pulmonary flow. In a ramp exercise test, an increase in heart rate will reflect positively on CO as long as the preload is kept intact. Since this may not be the fact in a TCPC circulation, any further increase in heart rate will more likely decrease the stroke volume. The lowering of PVR may increase pulmonary blood flow and thereby preload reserve in Fontan patients, and due to this pulmonary vasodilating therapy is interesting as a means to improve the Fontan circulation. The limited preload reserve is most likely to stem from PVR in the "healthy Fontans", but in cases where the Fontan conduit itself is restrictive, lowering the PVR would not be effective. As a consequence, patients with documented restrictive Fontan circuit on prior imaging are excluded from this study.

Pulmonary vasodilation therapy in the form of Sildenafil was previously evaluated in a placebo-controlled trial with TCPC patients both by Giardini et al. \[[@B18]\] and Goldberg et al. \[[@B26]\] showing an increase in peakVO~2~ and ventilatory efficiency, respectively. An open-label study on the effect of ERA in TCPC patients showed no effect on peakVO~2~\[[@B27]\]; however, the study population was relatively small with only 32 patients finishing with endpoint. Furthermore, the safety of ERA treatment to TCPC patients has recently been evaluated in an open-label pilot study \[[@B28]\]. Thus, the TEMPO-study is the first randomized, placebo-controlled study to evaluate the safety and effect of ERA on peakVO~2~in a TCPC population.

The primary endpoint of this trial is peakVO~2~; a test that is notoriously difficult to reproduce reliably, partly due to the fact that tests are often performed on different equipment, with different staff present, and with different levels of motivation. The quality of the primary endpoint data is of utmost importance, and testing all patients at the same location, with the same equipment and staff should secure the highest level of inter-test reliability.

In order to get a better understanding of the effect or lack of effect of ERA on the Fontan circulation, this study uses the non-invasive estimate of CO during exercise proposed by Wassermann et al. \[[@B22]\]. Though proven very reliable in healthy individuals as well as in patients with chronic heart failure \[[@B29],[@B30]\], this method has to the investigators' knowledge not yet been validated in Fontan patients. However, considering the nature of the method it is quite sane to assume that it will be as accurate and precise in Fontan patients as it is in chronic heart failure and healthy individuals.

The method is based on the fact that the difference in blood O~2~ content from arterial to mixed venous (C\[a-vDO~2~\]) develops linearly in relation to change in oxygen consumption (VO~2~) from rest (0%) to maximum uptake (100%) by the following regression line:

$$C\left( {a - vD_{O_{2}}} \right) = 5.72 + 0.105*\%{\overset{˙}{V}}_{O_{2\max}}; \cdot r = 0.94$$

VO~2~ is measured continuously, so CO can be calculated using the direct Fick method:

$${CO} = \frac{{\overset{˙}{V}O}_{2}}{C\left( {a-vD}_{O_{2}} \right)}$$

In Fontan patients without significant shunts, virtually all the blood passes through the pulmonary circulation, as is the case in a biventricular circulation without shunts. None of the assumptions of the method are violated in the Fontan circulation without shunts.
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Monitoring
----------

The study complies with the standards of Good Clinical Practice ICH-GCP. The GCP unit of Copenhagen monitors all aspects of the study according to the guidelines of ICH-GCP including initiation visit, planned intermediary control visits and end-of-study visit. Furthermore they can make visits unannounced if need be.
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